DICE Therapeutics (NASDAQ:DICE) Rating Lowered to Sell at Zacks Investment Research

DICE Therapeutics (NASDAQ:DICEGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “DICE Therapeutics Inc. is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif. “

NASDAQ DICE opened at $17.48 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 29.77 and a quick ratio of 29.77. The firm has a 50 day simple moving average of $18.95 and a 200-day simple moving average of $22.00. DICE Therapeutics has a one year low of $13.39 and a one year high of $40.50.

DICE Therapeutics (NASDAQ:DICEGet Rating) last issued its quarterly earnings results on Monday, March 21st. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.14. Equities research analysts expect that DICE Therapeutics will post -2.34 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in DICE. RA Capital Management L.P. purchased a new stake in shares of DICE Therapeutics during the third quarter worth approximately $170,592,000. Northpond Ventures LLC acquired a new position in DICE Therapeutics during the 4th quarter worth approximately $83,343,000. Janus Henderson Group PLC purchased a new stake in shares of DICE Therapeutics in the 3rd quarter valued at approximately $58,627,000. Deep Track Capital LP acquired a new stake in shares of DICE Therapeutics in the 4th quarter valued at $33,941,000. Finally, BlackRock Inc. lifted its position in shares of DICE Therapeutics by 0.6% during the 1st quarter. BlackRock Inc. now owns 860,540 shares of the company’s stock worth $16,462,000 after purchasing an additional 5,245 shares during the last quarter. 82.91% of the stock is owned by institutional investors and hedge funds.

About DICE Therapeutics (Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.

See Also

Get a free copy of the Zacks research report on DICE Therapeutics (DICE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.